ProPhase Labs, Inc. Capital Expenditures Incurred but Not yet Paid
ProPhase Labs, Inc. (PRPH) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-10.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2024-05-10
- ProPhase Labs, Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-03-31 was $1.62M.
- ProPhase Labs, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-03-31 was $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month |
|---|---|
| 2024-03-31 | $0.00 10-Q · filed 2024-05-10 |
| 2023-03-31 | $1.62M 10-Q · filed 2024-05-10 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |